^
    Back
    Association details:
    Biomarker:CD19 expression
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:JCAR014 (CD19-targeted CAR-T immunotherapy)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

    Excerpt:
    ...- Evidence of CD19 expression by immunohistochemistry or flow cytometry on any prior or current tumor specimen or high likelihood of CD19 expression based on disease histology...
    Trial ID:
    NCT03103971
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    Excerpt:
    ...- Evidence of CD19 expression on any prior or current tumor specimen or a high likelihood of CD19 expression based on disease histology...
    Trial ID:
    NCT02706405
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

    Excerpt:
    ...- Patients with CD19 expressing acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL)...
    Trial ID:
    RG9213011
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2022
    Title:

    CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma Using a Fully Human CD19-Targeted Single Chain Variable Fragment: Results of a First-in-Human Phase I/II Study

    Published date:
    11/03/2022
    Excerpt:
    In the efficacy-evaluable set (n=23), the overall (OR) and complete response (CR) rates at day 28 were 74% and 52%, respectively. After a median follow-up of 15 months, the 12-month progression-free survival (PFS) and overall survival (OS) were 43% and 86%, respectively. In pts in CR at day 28, the 12-month PFS was 71% (Figure A). In responders with subsequent disease progression, CD19 expression was confirmed in 3 of 3 of pts with available data (100%)...JCAR021, a fully-human scFv CD19-targeted CAR T-cell product, was dose-escalated to the RP2D with manageable toxicities in pts with R/R LBCL.
    Secondary therapy:
    cyclophosphamide + fludarabine oral
    DOI:
    https://doi.org/10.1182/blood-2022-157826
    Trial ID:
    NCT03103971